Literature DB >> 26123363

The role of regulatory T cells and microglia in glioblastoma-associated immunosuppression.

Alfred P See1, Jonathon J Parker, Allen Waziri.   

Abstract

Cell-mediated suppression of anti-tumor immunity is multifactorial in patients with cancer, and recent studies have focused on several distinct cellular agents that are associated with this phenomenon. This review will focus on the potential role of regulatory T cells (Tregs) and microglia in the suppression of cellular immunity observed in patients with glioblastoma. We discuss the ontogeny, basic biology, evidence for activity, and potential clinical options for targeting Tregs and microglia as part of immunotherapy in affected patients.

Entities:  

Mesh：

Year:  2015        PMID： 26123363     DOI： 10.1007/s11060-015-1849-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  72 in total

1.  IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo.

Authors:  M Hara; C I Kingsley; M Niimi; S Read; S E Turvey; A R Bushell; P J Morris; F Powrie; K J Wood
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

2.  Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors.

Authors:  Angelica Facoetti; Rosanna Nano; Paola Zelini; Patrizia Morbini; Eugenio Benericetti; Mauro Ceroni; Michael Campoli; Soldano Ferrone
Journal:  Clin Cancer Res       Date:  2005-12-01       Impact factor: 12.531

3.  All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.

Authors:  Noweeda Mirza; Mayer Fishman; Ingo Fricke; Mary Dunn; Anthony M Neuger; Timothy J Frost; Richard M Lush; Scott Antonia; Dmitry I Gabrilovich
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

4.  Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity.

Authors:  Dongchang Zhao; Darya Alizadeh; Leying Zhang; Wei Liu; Omar Farrukh; Edwin Manuel; Don J Diamond; Behnam Badie
Journal:  Clin Cancer Res       Date:  2010-11-18       Impact factor: 12.531

Review 5.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

6.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.

Authors:  Jason D Fontenot; Marc A Gavin; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2003-03-03       Impact factor: 25.606

7.  IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival.

Authors:  Derek A Wainwright; Irina V Balyasnikova; Alan L Chang; Atique U Ahmed; Kyung-Sub Moon; Brenda Auffinger; Alex L Tobias; Yu Han; Maciej S Lesniak
Journal:  Clin Cancer Res       Date:  2012-08-29       Impact factor: 12.531

8.  Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta.

Authors:  K Nakamura; A Kitani; W Strober
Journal:  J Exp Med       Date:  2001-09-03       Impact factor: 14.307

9.  TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function.

Authors:  Liang Zhou; Jared E Lopes; Mark M W Chong; Ivaylo I Ivanov; Roy Min; Gabriel D Victora; Yuelei Shen; Jianguang Du; Yuri P Rubtsov; Alexander Y Rudensky; Steven F Ziegler; Dan R Littman
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

10.  Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma.

Authors:  Sergei Kusmartsev; Zhen Su; Axel Heiser; Jens Dannull; Evgeniy Eruslanov; Hubert Kübler; Donna Yancey; Philip Dahm; Johannes Vieweg
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531
View more
  22 in total

1.  Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma.

Authors:  Manmeet S Ahluwalia; Stephanie Bou-Anak; Monica E Burgett; Nehaw Sarmey; Divya Khosla; Saurabh Dahiya; Robert J Weil; Eunnyung Bae; Ping Huang; Mary McGraw; Lisa M Grove; Mitchell A Olman; Richard A Prayson; John H Suh; G Yancey Gillespie; Jill Barnholtz-Sloan; Amy S Nowacki; Gene H Barnett; Candece L Gladson
Journal:  J Neurooncol       Date:  2016-11-17       Impact factor: 4.130

Review 2.  Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.

Authors:  Ryan D Salinas; Joseph S Durgin; Donald M O'Rourke
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

Review 3.  Multidimensional communication in the microenvirons of glioblastoma.

Authors:  Marike L Broekman; Sybren L N Maas; Erik R Abels; Thorsten R Mempel; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Rev Neurol       Date:  2018-08       Impact factor: 42.937

Review 4.  Immunotherapy of Primary Brain Tumors: Facts and Hopes.

Authors:  Robin A Buerki; Zinal S Chheda; Hideho Okada
Journal:  Clin Cancer Res       Date:  2018-06-05       Impact factor: 12.531

5.  Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model.

Authors:  Annabelle Cikankowitz; Anne Clavreul; Clément Tétaud; Laurent Lemaire; Audrey Rousseau; Nicolas Lepareur; Djamel Dabli; Francis Bouchet; Emmanuel Garcion; Philippe Menei; Olivier Couturier; François Hindré
Journal:  J Neurooncol       Date:  2016-10-25       Impact factor: 4.130

6.  Coculture Assays to Study Macrophage and Microglia Stimulation of Glioblastoma Invasion.

Authors:  Salvatore Coniglio; Ian Miller; Marc Symons; Jeffrey E Segall
Journal:  J Vis Exp       Date:  2016-10-20       Impact factor: 1.355

7.  Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma.

Authors:  Wen-Hao Hsu; Fatima Khan; Madeline Dunterman; Lizhi Pang; Wenjing Xuan; Derek A Wainwright; Atique U Ahmed; Amy B Heimberger; Maciej S Lesniak; Peiwen Chen
Journal:  Cancer Immunol Res       Date:  2022-06-03       Impact factor: 12.020

8.  Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor Microenvironment.

Authors:  Peiwen Chen; Wen-Hao Hsu; Andrew Chang; Zhi Tan; Zhengdao Lan; Ashley Zhou; Denise J Spring; Frederick F Lang; Y Alan Wang; Ronald A DePinho
Journal:  Cancer Discov       Date:  2020-01-09       Impact factor: 38.272

9.  Regulatory T cells promote glioma cell stemness through TGF-β-NF-κB-IL6-STAT3 signaling.

Authors:  Shasha Liu; Chaoqi Zhang; Boqiao Wang; Huanyu Zhang; Guohui Qin; Congcong Li; Ling Cao; Qun Gao; Yu Ping; Kai Zhang; Jingyao Lian; Qitai Zhao; Dan Wang; Zhen Zhang; Xuan Zhao; Li Yang; Lan Huang; Bo Yang; Yi Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-02-12       Impact factor: 6.968

Review 10.  Focused ultrasound-aided immunomodulation in glioblastoma multiforme: a therapeutic concept.

Authors:  Or Cohen-Inbar; Zhiyuan Xu; Jason P Sheehan
Journal:  J Ther Ultrasound       Date:  2016-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.